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Cost Modeling of a Downstream mAb Design Space: Stainless Steel Batch  
and Single-Use Batch vs. an Integrated Continuous Platform 
Jonathan Hummel, Mark Pagkaliwangan, Xhorxhi Gjoka, Rene Gantier, Mark Schofield; Pall Life Sciences, 20 Walkup Drive, Westborough, MA 01581, USA
Pall Life Sciences’ integrated, continuous downstream monoclonal antibody (mAb) platform 
is modeled in the BioSolveu Process. Supporting information comes from a real, process 
development scale continuous platform. Traditional batch downstream processes are also 
modeled in both stainless steel (SS) and single-use (SU) forms. 
  The costs associated with these three downstream strategies are compared across a range  
of fed-batch bioreactor volumes, titers, and number of batches per year. 
   
Stainless Steel Batch
  The most traditional process utilizing higher capital equipment that often requires some level of 
dedicated offline cleaning. 
  SS fluid preparation and storage are used, with product hold wherever necessary. 
 Single-Use Batch
  This process has similar unit operation timing and personnel assignment as stainless, but 
utilizes more disposable components, particularly for chromatography and filtration steps. 
  Single-use biocontainer systems are used for fluid preparation and storage below 2000 L. 
Integrated Continuous Bioprocessing (ICB) Platform
  Utilizes Pall Life Sciences’ existing and planned continuous and single-use technology to purify 
the same feed in under 24 hours (48 hours for the 12000 L scenarios). 
  Biocontainer systems are used for fluid preparation and storage below 2000 L. 
The following high-level assumptions were applied for all three models:
  Greenfield / new facility capital estimation including floor costs and supporting facility 
equipment (single product, 10 year lifetime, 10% final value, 12% interest).
  Only downstream costs are modeled (upstream impact presumed equal).
  Moderately challenging clarification assumed (~40 m2 depth / 1000 L feed).
  Final formulation membranes are reused per year (campaign).
  Same downstream mAb yield and final target titer for each process.
  Higher personnel assignment for the continuous process to account for operation of many 
units in parallel without full, process-wide automation.
Table 1
The commercial design space was explored for SS batch, SU batch and ICB downstream 
processing scenarios.
Commercial Factors (17 – 1600 kg/year)
Volume (L) 2000 6000 12000
Titer (g/L) 1 5 9
Batches/Year 15 20 25
Sorbent Reuse             * 200 cycles or 3 years
*Chromatography membrane adsorbers are reused for max duration
Figure 1
Contour plots of the annual CoGs associated with SS batch (A), SU batch (B), and ICB platform 
(C) vs bioreactor titer and volume at 20 batches / year. The change in color indicates the 
approximate median annual cost of the design space.
  SU batch exhibits notable savings over SS batch, however the ICB platform has the lowest 
costs across the entire range of bioreactor titer and volume. 
  The cost advantage of the ICB platform increases with increasing bioreactor titer and volume.
Figure 2
A comparison of the CoGs per gram of each process at a single case: 20 batches / year of  
6000 L at 5 g/L. The costs are broken down by downstream section.
  16 – 30% total ICB platform savings coming from the clarification, purification, and polishing 
sections ($2.2 – 4.7M savings / year). 
  The Cadence Acoustic Separator is responsible for capital reductions in clarification.
  The Cadence BioSMB system is responsible for notable savings in purification and polishing.
Figure 3
A comparison of the net present cost (NPC) for each process at a 5 g/L titer and the full range of 
commercial volumes and batches / year. 
 
Under the set of assumptions modeled here: 
  The ICB platform has the lowest CoGs across the entire commercial space explored (not all 
data was shown). 
  Major sources of savings in the process included the Cadence BioSMB s ystem, which offers 
reduced chromatography sorbent volume and lower buffer consumption.  
  Another source of savings is the Cadence Acoustic Separator, which offers reduced capital 
costs in some sections of the design space and reduced consumable costs in the others. 
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